Amarin Corporation PLC
NASDAQ:AMRN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.52
1.35
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AMRN stock under the Base Case scenario is 1.1 USD. Compared to the current market price of 0.52 USD, Amarin Corporation PLC is Undervalued by 53%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Amarin Corporation PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AMRN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Amarin Corporation PLC
Balance Sheet Decomposition
Amarin Corporation PLC
Current Assets | 650.2m |
Cash & Short-Term Investments | 305.7m |
Receivables | 112.6m |
Other Current Assets | 231.8m |
Non-Current Assets | 100.4m |
PP&E | 8m |
Intangibles | 17.1m |
Other Non-Current Assets | 75.3m |
Current Liabilities | 201.6m |
Accounts Payable | 40.5m |
Accrued Liabilities | 161m |
Non-Current Liabilities | 17.7m |
Other Non-Current Liabilities | 17.7m |
Earnings Waterfall
Amarin Corporation PLC
Revenue
|
241m
USD
|
Cost of Revenue
|
-104.9m
USD
|
Gross Profit
|
136.1m
USD
|
Operating Expenses
|
-180m
USD
|
Operating Income
|
-43.9m
USD
|
Other Expenses
|
4.5m
USD
|
Net Income
|
-39.3m
USD
|
Free Cash Flow Analysis
Amarin Corporation PLC
USD | |
Free Cash Flow | USD |
AMRN Profitability Score
Profitability Due Diligence
Amarin Corporation PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Amarin Corporation PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
AMRN Solvency Score
Solvency Due Diligence
Amarin Corporation PLC's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Amarin Corporation PLC's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMRN Price Targets Summary
Amarin Corporation PLC
According to Wall Street analysts, the average 1-year price target for AMRN is 1.02 USD with a low forecast of 1.01 USD and a high forecast of 1.05 USD.
Dividends
Current shareholder yield for AMRN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AMRN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics for cardiovascular disease management. The firm operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Contact
IPO
Employees
Officers
The intrinsic value of one AMRN stock under the Base Case scenario is 1.1 USD.
Compared to the current market price of 0.52 USD, Amarin Corporation PLC is Undervalued by 53%.